Cargando…

Refractory thyroid carcinoma: which systemic treatment to use?

The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Faugeras, Laurence, Pirson, Anne-Sophie, Donckier, Julian, Michel, Luc, Lemaire, Julien, Vandervorst, Sebastien, D’Hondt, Lionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788129/
https://www.ncbi.nlm.nih.gov/pubmed/29399055
http://dx.doi.org/10.1177/1758834017752853
_version_ 1783296056758370304
author Faugeras, Laurence
Pirson, Anne-Sophie
Donckier, Julian
Michel, Luc
Lemaire, Julien
Vandervorst, Sebastien
D’Hondt, Lionel
author_facet Faugeras, Laurence
Pirson, Anne-Sophie
Donckier, Julian
Michel, Luc
Lemaire, Julien
Vandervorst, Sebastien
D’Hondt, Lionel
author_sort Faugeras, Laurence
collection PubMed
description The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate. However, in the past few years, several systemic therapies, primarily targeted, have emerged to improve the overall survival of these patients. Alternative treatments are also of interest, namely peptide receptor radionuclide therapy or immunotherapy.
format Online
Article
Text
id pubmed-5788129
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-57881292018-02-02 Refractory thyroid carcinoma: which systemic treatment to use? Faugeras, Laurence Pirson, Anne-Sophie Donckier, Julian Michel, Luc Lemaire, Julien Vandervorst, Sebastien D’Hondt, Lionel Ther Adv Med Oncol Review The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate. However, in the past few years, several systemic therapies, primarily targeted, have emerged to improve the overall survival of these patients. Alternative treatments are also of interest, namely peptide receptor radionuclide therapy or immunotherapy. SAGE Publications 2018-01-23 /pmc/articles/PMC5788129/ /pubmed/29399055 http://dx.doi.org/10.1177/1758834017752853 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Faugeras, Laurence
Pirson, Anne-Sophie
Donckier, Julian
Michel, Luc
Lemaire, Julien
Vandervorst, Sebastien
D’Hondt, Lionel
Refractory thyroid carcinoma: which systemic treatment to use?
title Refractory thyroid carcinoma: which systemic treatment to use?
title_full Refractory thyroid carcinoma: which systemic treatment to use?
title_fullStr Refractory thyroid carcinoma: which systemic treatment to use?
title_full_unstemmed Refractory thyroid carcinoma: which systemic treatment to use?
title_short Refractory thyroid carcinoma: which systemic treatment to use?
title_sort refractory thyroid carcinoma: which systemic treatment to use?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788129/
https://www.ncbi.nlm.nih.gov/pubmed/29399055
http://dx.doi.org/10.1177/1758834017752853
work_keys_str_mv AT faugeraslaurence refractorythyroidcarcinomawhichsystemictreatmenttouse
AT pirsonannesophie refractorythyroidcarcinomawhichsystemictreatmenttouse
AT donckierjulian refractorythyroidcarcinomawhichsystemictreatmenttouse
AT michelluc refractorythyroidcarcinomawhichsystemictreatmenttouse
AT lemairejulien refractorythyroidcarcinomawhichsystemictreatmenttouse
AT vandervorstsebastien refractorythyroidcarcinomawhichsystemictreatmenttouse
AT dhondtlionel refractorythyroidcarcinomawhichsystemictreatmenttouse